Last reviewed · How we verify

NCT06687720

A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic Supplementation in the Management of Irritable Bowel Syndrome With Protein Digestion.

Not yet recruiting NA Last updated 14 November 2024
What this trial tests

NA trial testing MetBroma in Irritable Bowel Syndrome in 18 participants. Not yet recruiting.

Timeline
30 November 2024
Primary endpoint
30 November 2024
30 November 2024

Quick facts

Lead sponsorNovoBliss Research Pvt Ltd
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment18
Start date30 November 2024
Primary completion30 November 2024
Estimated completion30 November 2024

Drugs / interventions tested

Conditions studied

Sponsor

NovoBliss Research Pvt Ltd — full company profile →

Who can join

Adults 18 to 60, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, two-arm, prospective, interventional, in-use safety and efficacy study of an oral probiotic supplementation in adult subjects having irritable bowel syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

Other NovoBliss Research Pvt Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06687720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing